Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

A potentially deleterious new CYP2C9 polymorphism identified in an African American patient with major hemorrhage on warfarin therapy.

Goldstein JA, Blaisdell JA, Limdi NA.

Blood Cells Mol Dis. 2009 Mar-Apr;42(2):155-8. doi: 10.1016/j.bcmd.2008.10.011. Epub 2008 Dec 11. No abstract available.

2.

[The influence of CYP2C9 genetic polymorphism on the pharmacokinetics and pharmacodynamics of warfarin in patients with constant atrial fibrillation].

Sychev DA, Mikheeva IuA, Kropacheva ES, Ignat'ev IV, Bulytova IuM, Ramenskaia GV, Dobrovol'skiĭ AB, Panchenko EP, Kukes VG.

Klin Med (Mosk). 2007;85(1):57-60. Russian.

PMID:
17419358
3.

CYP2C9 promoter region single-nucleotide polymorphisms linked to the R150H polymorphism are functional suggesting their role in CYP2C9*8-mediated effects.

Cavallari LH, Vaynshteyn D, Freeman KM, Wang D, Perera MA, Takahashi H, Drozda K, Patel SR, Jeong H.

Pharmacogenet Genomics. 2013 Apr;23(4):228-31. doi: 10.1097/FPC.0b013e32835e95c7.

4.

Refining the use of warfarin through genetic testing.

Lee SC.

Int Angiol. 2008 Aug;27(4):271-3. No abstract available.

PMID:
18677287
5.

Genotype and adverse drug reactions to warfarin.

Byron KA, Dear AE.

Med J Aust. 2007 Jul 2;187(1):61-2. No abstract available.

PMID:
17605718
6.

Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study.

Perera MA, Cavallari LH, Limdi NA, Gamazon ER, Konkashbaev A, Daneshjou R, Pluzhnikov A, Crawford DC, Wang J, Liu N, Tatonetti N, Bourgeois S, Takahashi H, Bradford Y, Burkley BM, Desnick RJ, Halperin JL, Khalifa SI, Langaee TY, Lubitz SA, Nutescu EA, Oetjens M, Shahin MH, Patel SR, Sagreiya H, Tector M, Weck KE, Rieder MJ, Scott SA, Wu AH, Burmester JK, Wadelius M, Deloukas P, Wagner MJ, Mushiroda T, Kubo M, Roden DM, Cox NJ, Altman RB, Klein TE, Nakamura Y, Johnson JA.

Lancet. 2013 Aug 31;382(9894):790-6. doi: 10.1016/S0140-6736(13)60681-9. Epub 2013 Jun 5.

7.

The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans.

Perera MA, Gamazon E, Cavallari LH, Patel SR, Poindexter S, Kittles RA, Nicolae D, Cox NJ.

Clin Pharmacol Ther. 2011 Mar;89(3):408-15. doi: 10.1038/clpt.2010.322. Epub 2011 Jan 26.

8.

Factors influencing warfarin dose requirements in African-Americans.

Momary KM, Shapiro NL, Viana MA, Nutescu EA, Helgason CM, Cavallari LH.

Pharmacogenomics. 2007 Nov;8(11):1535-44.

PMID:
18034618
9.

Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin.

Limdi NA, McGwin G, Goldstein JA, Beasley TM, Arnett DK, Adler BK, Baird MF, Acton RT.

Clin Pharmacol Ther. 2008 Feb;83(2):312-21. Epub 2007 Jul 25.

10.

VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.

Shaw K, Amstutz U, Hildebrand C, Rassekh SR, Hosking M, Neville K, Leeder JS, Hayden MR, Ross CJ, Carleton BC.

Pediatr Blood Cancer. 2014 Jun;61(6):1055-62. doi: 10.1002/pbc.24932. Epub 2014 Jan 29.

PMID:
24474498
11.

CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing.

Scott SA, Jaremko M, Lubitz SA, Kornreich R, Halperin JL, Desnick RJ.

Pharmacogenomics. 2009 Aug;10(8):1243-55. doi: 10.2217/pgs.09.71.

12.

Genetics of warfarin dosing--one polymorphism at a time.

Alberts MJ.

Lancet. 2013 Aug 31;382(9894):749-51. doi: 10.1016/S0140-6736(13)60942-3. Epub 2013 Jun 5. No abstract available.

PMID:
23755829
13.

Delayed warfarin induced skin necrosis in a patient with poor warfarin metabolizing activity due to interrupted warfarin therapy.

Gaikwad T, Ghosh K, Shetty S.

Eur J Clin Pharmacol. 2013 Feb;69(2):293-4. doi: 10.1007/s00228-012-1332-4. Epub 2012 Jun 17. No abstract available.

PMID:
22706625
14.

Warfarin sensitivity genotyping: a review of the literature and summary of patient experience.

Moyer TP, O'Kane DJ, Baudhuin LM, Wiley CL, Fortini A, Fisher PK, Dupras DM, Chaudhry R, Thapa P, Zinsmeister AR, Heit JA.

Mayo Clin Proc. 2009 Dec;84(12):1079-94. doi: 10.4065/mcp.2009.0278. Review.

15.

Major bleeding caused by warfarin in a genetically susceptible patient.

Bloch A, Ben-Chetrit E, Muszkat M, Caraco Y.

Pharmacotherapy. 2002 Jan;22(1):97-101.

PMID:
11794436
16.

The VKORC1 and CYP2C9 genotypes are associated with over-anticoagulation during initiation of warfarin therapy in children.

Biss TT, Avery PJ, Williams MD, Brandão LR, Grainger JD, Kamali F.

J Thromb Haemost. 2013 Feb;11(2):373-5. doi: 10.1111/jth.12072. No abstract available.

17.

Pharmacogenetics of warfarin: current status and future challenges.

Wadelius M, Pirmohamed M.

Pharmacogenomics J. 2007 Apr;7(2):99-111. Epub 2006 Sep 19. Review.

PMID:
16983400
18.

A case of intolerance to warfarin dosing in an intermediate metabolizer of CYP2C9.

Lee SY, Kim JS, Kim JW.

Yonsei Med J. 2005 Dec 31;46(6):843-6.

19.

Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation.

Eckman MH, Rosand J, Greenberg SM, Gage BF.

Ann Intern Med. 2009 Jan 20;150(2):73-83.

PMID:
19153410
20.

A new algorithm to predict warfarin dose from polymorphisms of CYP4F2 , CYP2C9 and VKORC1 and clinical variables: derivation in Han Chinese patients with non valvular atrial fibrillation.

Wei M, Ye F, Xie D, Zhu Y, Zhu J, Tao Y, Yu F.

Thromb Haemost. 2012 Jun;107(6):1083-91. doi: 10.1160/TH11-12-0848. Epub 2012 Apr 26.

PMID:
22534826

Supplemental Content

Support Center